A nurse is preparing to administer methylergonovine IM for a client who had a vaginal delivery earlier that day. The nurse should explain to the client that this medication will help prevent which of the following? (Select onE.:

Choice A: Thromboembolic events are not prevented by methylergonovinE. Thromboembolic events are blood clots that can form in the veins or arteries and cause serious complications such as pulmonary embolism or strokE. Methylergonovine is a uterotonic agent that stimulates the contraction of the uterus and can actually increase the risk of thromboembolic events by causing vasoconstriction and hypertension.

Choice B: Postpartum hemorrhage is prevented by methylergonovinE. Postpartum hemorrhage is excessive bleeding after delivery that can result from uterine atony, retained placenta, or lacerations. Methylergonovine is a uterotonic agent that stimulates the contraction of the uterus and helps control the bleeding by compressing the blood vessels and expelling any placental fragments.

Choice C: Postpartum infection is not prevented by methylergonovinE. Postpartum infection is a bacterial infection that can affect the uterus, the vagina, the bladder, or the breast after delivery. Methylergonovine is a uterotonic agent that has no antibacterial activity and can actually increase the risk of infection by causing fever and chills.

Choice D: Hypertension is not prevented by methylergonovinE. Hypertension is high blood pressure that can cause complications such as preeclampsia, eclampsia, or strokE. Methylergonovine is a uterotonic agent that can actually cause or worsen hypertension by stimulating the alpha-adrenergic receptors and causing vasoconstriction.